Myriad Genetics is a molecular diagnostic company which focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The Company offers molecular diagnostic tests, including DNA sequencing tests for hereditary breast, ovarian, colorectal and uterine cancer, a protein quantification test for assessing the disease activity of rheumatoid arthritis, RNA expression tests for assessing the aggressiveness of prostate cancer, diagnosing melanoma, and a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients. It also provides biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries, and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis.

Type
Public
HQ
Salt Lake City, US
Founded
1991
Size (employees)
2,400 (est)
Website
myriad.com
Myriad Genetics was founded in 1991 and is headquartered in Salt Lake City, US
Report incorrect company information

Myriad Genetics Office Locations

Myriad Genetics has offices in Schiphol, London, Issy-les-Moulineaux, El Soto de la Moraleja and in 7 other locations
Salt Lake City, US (HQ)
Myriad Genetics, Inc. 320 Wakara Way
Austin, US
3300 Duval Rd
South San Francisco, US
341 Oyster Point Blvd
Issy-les-Moulineaux, FR
13 Rue Camille Desmoulins
Martinsried, DE
Bunsenstrasse 7
Planegg, DE
Fraunhoferstrasse 18a
Show all (11)
Report incorrect company information

Myriad Genetics Financials and Metrics

Myriad Genetics Financials

Myriad Genetics's revenue was reported to be $753.80 m in FY, 2016 which is a 4.2% increase from the previous period.
USD

Revenue (Q3, 2017)

196.9 m

Net income (Q3, 2017)

4.2 m

EBIT (Q3, 2017)

12.9 m

Market capitalization (25-Apr-2018)

2 b

Cash (31-Mar-2017)

123.8 m

EV

2.1 b
Myriad Genetics's current market capitalization is $2 b.
Annual
USDFY, 2014FY, 2015FY, 2016

Revenue

778.2 m723.1 m753.8 m

Revenue growth, %

(7%)4%

EBIT

274.4 m134.2 m166.8 m

EBIT margin, %

35%19%22%
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

202.5 m204.1 m182.9 m168.8 m184.4 m180 m183.5 m193.3 m190.5 m177.5 m196.5 m196.9 m

Operating expense total

119.6 m121.1 m127.6 m142.9 m148.1 m144.2 m140.2 m148.1 m147.9 m171.3 m183.3 m184 m

EBIT

82.9 m83 m55.3 m25.9 m36.3 m35.7 m43.3 m45.2 m42.6 m6.2 m13.2 m12.9 m

EBIT margin, %

41%41%30%15%20%20%24%23%22%3%7%7%
Annual
USDFY, 2014FY, 2015FY, 2016

Cash

64.8 m64.1 m68.5 m

Accounts Receivable

3.8 m1.9 m3.3 m

Inventories

23.9 m25.1 m38.3 m

Current Assets

322.4 m283.6 m314.5 m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

85 m71.6 m85.8 m69.8 m59.7 m55.2 m87.4 m134.7 m120.5 m86.9 m108.1 m123.8 m

Accounts Receivable

1.8 m3.5 m3.2 m11.2 m5.3 m3 m1.6 m5.1 m2.9 m4.6 m3.9 m4.4 m

Inventories

18.9 m24.8 m20.2 m29.4 m34.3 m29.1 m25.3 m53.9 m51.3 m47.4 m

Current Assets

458.7 m454.5 m338.2 m335.4 m320.1 m282.4 m307.3 m375.5 m372.4 m322.9 m341.6 m348.3 m
Annual
USDFY, 2014FY, 2015FY, 2016

Net Income

176.2 m80.2 m125.3 m

Depreciation and Amortization

13.8 m25 m26.7 m

Inventories

(16 m)(800 k)(15 m)

Accounts Payable

(1.5 m)(3.1 m)(3.1 m)
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Net Income

55.5 m50.4 m36.8 m16 m24 m21.5 m26.6 m30.3 m32.6 m(1.2 m)5.9 m4.2 m

Inventories

24.8 m20.2 m29.4 m34.3 m29.1 m25.3 m53.9 m51.3 m47.4 m

Accounts Payable

25.7 m16.8 m18 m15.8 m16.5 m13.8 m19.9 m22.9 m26.8 m
USDY, 2017

EV/EBIT

161.7 x

Revenue/Employee

89.3 k

Financial Leverage

1.7 x
Show all financial metrics
Report incorrect company information